IASLC issues statement on lung cancer screening with low-dose computed tomography

December 4, 2018 | Cancer Screening

The International Association for the Study of Lung Cancer (IASLC) recently issued a statement on lung cancer screening with low-dose computed tomography (LDCT) based on results from the Dutch-Belgian NELSON lung cancer screening trial. The IASLC Early Detection and Screening Committee now affirms the strength of evidence arising from two large, well designed and well executed randomized trials that LDCT screening in high risk individuals can significantly reduce lung cancer mortality.

The full article is available here.

Screening programs have been shown to be a key factor in reducing the risk of dying from certain cancers. Unfortunately, a recent study also showed that less than 2% of patients eligible are receiving lung cancer screenings. The HealthMyne platform helps organizations overcome barriers like poor internal workflows and staffing/time limitations to provide more and better lung screening programs that save lives. Learn more.